Wave Keeps Neuro Focus Via Pfizer Collaboration For Five Metabolic Targets
Wave Life Sciences Ltd. entered into a collaboration agreement with Pfizer Inc. for the discovery and development of nucleic acid therapeutics addressing five metabolic disease targets, adding $40m in upfront cash to its balance sheet that will help the newly public biotechnology firm keep its in-house focus on rare, genetic neurological and neuromuscular diseases.
You may also be interested in...
Start-Up Quarterly Statistics, Q2 2016
A review of biopharma start-up dealmaking and financing from April through June 2016, based on data from Strategic Transactions.
Biotech IPO Window Closed In November As Returns And Prices Plunged
Did the window for US initial public offerings by biotechnology companies suddenly slammed shut in late November? Now that everyone's back at work after the Thanksgiving holiday, that appears to be the case, and it doesn't look like the biotech IPO window will reopen anytime soon.
Is the Biotech IPO Window Closing?
Drug developers are filing for initial public offerings at a brisk pace in October despite falling biotechnology stock values and the struggle to price first-time offerings attractively, which begs the question: Are biotech companies afraid that the IPO window is about to close?